文献速递冠心病瓣膜病与结构性心脏病

缺血性心脏病再评估:冠状动脉微血管功能障碍的核心作用

Reappraisal of Ischemic Heart Disease.
PubMed 文献 · Circulation · 2018-01-01

本文综述冠状动脉微血管功能障碍在缺血性心脏病发病中的核心作用,涵盖其功能与结构机制、微血管心绞痛的临床特征及诊断治疗策略。微血管心绞痛见于无阻塞性冠脉病及阻塞性冠脉病患者,影响生活质量和预后,治疗仍具挑战。

要点

  • 冠状动脉微血管功能障碍是心绞痛的重要致病机制,可见于无阻塞性冠脉病者。
  • 微血管心绞痛表现为劳力或静息胸痛,伴冠脉血流储备降低或微血管痉挛。
  • 微血管心绞痛在稳定心绞痛及血运重建后持续心绞痛患者中占相当比例。

核心结论

  • 冠状动脉微血管功能障碍在缺血性心脏病发病中起核心致病作用,是微血管心绞痛的基础。

研究设计与样本

  • 本文为综述,讨论冠状动脉微血管功能障碍在缺血性心脏病中的作用、微血管心绞痛临床特征及诊治策略。

主要发现

  • 冠状动脉微血管的异常扩张反应、微血管痉挛及血管外压迫力是慢性和急性缺血性心脏病的致病机制。
  • 微血管心绞痛患者构成接受诊断性冠状动脉造影的稳定心绞痛患者及成功血运重建后持续心绞痛患者的相当比例。
  • 冠状动脉微血管功能障碍也常导致心肌病、心脏瓣膜病以及Takotsubo综合征和无阻塞性冠脉病心肌梗死等急性冠脉综合征患者的心绞痛。
  • 稳定型微血管心绞痛典型表现为劳力或静息胸痛,伴冠脉血流储备降低或微血管痉挛,影响女性和男性。

临床怎么用

  • 诊断心肌缺血及评估冠脉血流储备降低和微血管痉挛的功能与结构病因的检查,有助于在日常临床实践中识别更多微血管心绞痛病例。
  • 部分抗心绞痛药物可能有益,但冠状动脉微血管功能障碍的治疗仍是重大挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In recent years, it has become apparent that coronary microvascular dysfunction plays a pivotal pathogenic role in angina pectoris. Functional and structural mechanisms can affect the physiological function of the coronary microvasculature and lead to myocardial ischemia in people without coronary atheromatous disease and also in individuals with obstructive coronary artery disease. Abnormal dilatory responses of the coronary microvessels, coronary microvascular spasm, and extravascular compressive forces have been identified as pathogenic mechanisms in both chronic and acute forms of ischemic heart disease. The condition characterized by anginal symptoms and evidence of myocardial ischemia triggered by coronary microvascular dysfunction, in the absence of obstructive coronary disease, is known as microvascular angina. The concept of microvascular angina, however, may extend further to include patients with obstructive coronary artery disease and individuals with angina after coronary revascularization or heart transplantation because coronary microvascular dysfunction contributes to myocardial ischemia in many such patients. Patients with microvascular angina constitute a sizeable proportion of all cases of stable angina undergoing diagnostic coronary angiography and of those with persisting angina after successful coronary revascularization. Coronary microvascular dysfunction is also often responsible for angina in individuals with cardiomyopathy and heart valve disease as well as acute coronary syndrome cases such as Takotsubo syndrome and myocardial infarction with no obstructive coronary artery disease. Patients with stable microvascular angina present typically with effort or rest chest pain and a reduced coronary flow reserve or microvascular spasm. This condition, which affects women and men, can markedly impair quality of life and prognosis and represents a substantial cost burden to healthcare systems and individuals alike. In recent years, progress in the diagnosis of myocardial ischemia and the use of tests to investigate functional and structural causes for a reduced coronary flow reserve and microvascular spasm have allowed the identification of an increased number of cases of microvascular angina in everyday clinical practice. Although some of the available anti-anginal drugs may be helpful, treatment of coronary microvascular dysfunction remains a major challenge. The present article discusses the fundamental role that coronary microvascular dysfunction plays in the pathogenesis of ischemic heart disease, the clinical characteristics of patients presenting with microvascular angina, and possible diagnostic and therapeutic strategies.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Kaski JC, Crea F, Gersh BJ, et al. Reappraisal of Ischemic Heart Disease. Circulation. 2018. PMID: 30354347. doi:10.1161/CIRCULATIONAHA.118.031373

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。